Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Anemia in the ICU: are your patients needin’ erythropoetin"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Anemia in the ICU: are your patients needin’ erythropoetin? | Hecht and Boujoukos Critical Care 2010 14 332 http ccforum.eom content 14 6 332 CRITICAL CARE JOURNAL CLUB CRITIQUE L Anemia in the ICU are your patients needin erythropoetin David Hecht and Arthur Boujoukos University of Pittsburgh Department of Critical Care Medicine Evidence-Based Medicine Journal Club edited by Sachin Yende Extended abstract Citation Corwin HL Gettinger A Fabian TC May A Pearl RG Heard S An R Bowers PJ Burton P Klausner MA and Corwin MJ for the EPO Critical Care Trials Group Efficacy and Safety of Epoetin Alfa in Critically Ill Patients NEngl J Med 2007 357 965-76 Background Anemia which is common in the critically ill is often treated with red-cell transfusions which are associated with poor clinical outcomes. We hypothesized that therapy with recombinant human erythropoietin epoetin alfa might reduce the need for red-cell transfusions. Methods Objective Evaluate the efficacy of epoetin alfa in reducing the packed red blood cell transfusion requirement in critically ill patients. Design Prospective randomized double blind placebo controlled multi-center trial Setting 115 medical centers throughout the United States. Subjects 1460 patients that had been admitted to medical surgical or trauma intensive care units. Inclusion criteria included age 18 years or greater patients remained in the ICU for two days and hemoglobin level less than 12 gm dl. Statistical analysis was performed for the entire group as well as subgroup analysis according to the type of ICU to which the patient was admitted the subgroup analysis was included in the initial study design . Intervention After enrollment patients randomized to the study group received epoetin alfa 40 000 units SQ on study day 1 8 and 15. The drug was withheld if the hemoglobin level was greater than 12 gm dl at the time of scheduled administration. Patients randomized to the Correspondence boujoukosaj@upmc.edu Department of Critical Care Medicine 612A Scaife Hall 3550 .